AR121864A1 - Composiciones anticonceptivas con efectos adversos reducidos - Google Patents
Composiciones anticonceptivas con efectos adversos reducidosInfo
- Publication number
- AR121864A1 AR121864A1 ARP210101014A ARP210101014A AR121864A1 AR 121864 A1 AR121864 A1 AR 121864A1 AR P210101014 A ARP210101014 A AR P210101014A AR P210101014 A ARP210101014 A AR P210101014A AR 121864 A1 AR121864 A1 AR 121864A1
- Authority
- AR
- Argentina
- Prior art keywords
- combined oral
- reduced risk
- adverse effects
- contraceptive
- reduced adverse
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un anticonceptivo oral combinado con un riesgo reducido de efectos secundarios, incluido un riesgo reducido de prolongación del intervalo QT, un riesgo reducido de disminución de testosterona y un riesgo reducido de niveles elevados de proteína C reactiva en comparación con otros anticonceptivos orales combinados. El anticonceptivo oral combinado de estetrol / drospirenona descrito en el presente documento muestra una farmacocinética favorable para el componente progestágeno. El uso de un componente estrogénico específico en el anticonceptivo oral combinado conlleva múltiples beneficios respecto a los anticonceptivos orales combinados disponibles actualmente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20169870 | 2020-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121864A1 true AR121864A1 (es) | 2022-07-20 |
Family
ID=70292885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210101014A AR121864A1 (es) | 2020-04-16 | 2021-04-16 | Composiciones anticonceptivas con efectos adversos reducidos |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220211722A1 (es) |
EP (1) | EP4135709A1 (es) |
JP (1) | JP2023526580A (es) |
KR (1) | KR20230004637A (es) |
CN (1) | CN115666582A (es) |
AR (1) | AR121864A1 (es) |
AU (1) | AU2021255908A1 (es) |
BR (1) | BR112022020710A2 (es) |
CA (1) | CA3177556A1 (es) |
IL (1) | IL297282A (es) |
MX (1) | MX2022012917A (es) |
TW (1) | TW202203935A (es) |
UY (1) | UY39175A (es) |
WO (1) | WO2021209591A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO3106148T3 (es) | 2015-06-18 | 2018-08-11 | ||
EP3701944B1 (en) | 2015-06-18 | 2021-12-08 | Estetra SRL | Orodispersible dosage unit containing an estetrol component |
CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200046729A1 (en) * | 2016-08-05 | 2020-02-13 | Estetra Sprl | Methods using combined oral contraceptive compositions with reduced cardiovascular effects |
JOP20200169A1 (ar) * | 2018-02-07 | 2020-07-07 | Estetra Sprl | تركيبة لمنع الحمل بتأثيرات منخفضة على القلب والأوعية |
-
2021
- 2021-04-09 TW TW110112923A patent/TW202203935A/zh unknown
- 2021-04-16 UY UY0001039175A patent/UY39175A/es unknown
- 2021-04-16 KR KR1020227039906A patent/KR20230004637A/ko not_active Application Discontinuation
- 2021-04-16 MX MX2022012917A patent/MX2022012917A/es unknown
- 2021-04-16 CN CN202180038196.1A patent/CN115666582A/zh active Pending
- 2021-04-16 AU AU2021255908A patent/AU2021255908A1/en active Pending
- 2021-04-16 CA CA3177556A patent/CA3177556A1/en active Pending
- 2021-04-16 EP EP21716951.5A patent/EP4135709A1/en active Pending
- 2021-04-16 IL IL297282A patent/IL297282A/en unknown
- 2021-04-16 AR ARP210101014A patent/AR121864A1/es unknown
- 2021-04-16 BR BR112022020710A patent/BR112022020710A2/pt unknown
- 2021-04-16 JP JP2022562639A patent/JP2023526580A/ja active Pending
- 2021-04-16 WO PCT/EP2021/059890 patent/WO2021209591A1/en unknown
-
2022
- 2022-03-22 US US17/701,588 patent/US20220211722A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2022012917A (es) | 2022-11-16 |
US20220211722A1 (en) | 2022-07-07 |
WO2021209591A1 (en) | 2021-10-21 |
KR20230004637A (ko) | 2023-01-06 |
CA3177556A1 (en) | 2021-10-21 |
EP4135709A1 (en) | 2023-02-22 |
JP2023526580A (ja) | 2023-06-22 |
TW202203935A (zh) | 2022-02-01 |
AU2021255908A1 (en) | 2022-10-27 |
CN115666582A (zh) | 2023-01-31 |
BR112022020710A2 (pt) | 2022-12-20 |
UY39175A (es) | 2022-04-29 |
IL297282A (en) | 2022-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY39175A (es) | Composiciones anticonceptivas con efectos adversos reducidos | |
HN2008000621A (es) | Metodo para la anticopcepcion hormonal preventiva bajo demanda | |
GT200900090A (es) | Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o incrementar la libido femenina | |
CL2019000477A1 (es) | Un esteroide 19 nor-c21-n-pirazolilo c3,3- disustituido cristalino. | |
CO2019000672A2 (es) | Procedimiento de tratamiento de dismenorrea y dolor menstrual | |
ECSP055574A (es) | Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas. | |
AR074528A1 (es) | Dispositivos intravaginales con un soporte rigido, metodos para su fabricacion y sus usos | |
AR054123A1 (es) | Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato | |
PE20120860A1 (es) | Combinacion farmaceutica que comprende levonorgestrel en combinacion con piroxicam, indometacina o diclofenaco | |
PE20211239A1 (es) | Compuestos y sus usos para aliviar sintomas asociados a la menopausia | |
CU20090004A7 (es) | Composición farmacéutica que contiene un ácido tetrahidrofólico | |
CL2020002017A1 (es) | Composición anticonceptiva con efectos cardiovasculares reducidos. | |
GT200600307A (es) | Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina | |
Haddad et al. | Contraceptive methods and risk of HIV acquisition or female-to-male transmission | |
CL2020002252A1 (es) | Formulación oftálmica. | |
PE20060318A1 (es) | Forma de administracion para la contracepcion hormonal | |
BR112012025066A2 (pt) | mistura fluidificante para composição hidráulica | |
AR095691A1 (es) | FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO | |
CO5580789A2 (es) | Composicion que comprende una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno y su uso para el tratamiento de endometriosis | |
BR112019025591A2 (pt) | Composição farmacêutica compreendendo conjugado de fármaco-anticorpo c-met e uso do mesmo | |
AR120976A1 (es) | Sistema para proporcionar un control de la natalidad | |
AR095834A1 (es) | Forma de dosificación de un antagonista del receptor de progesterona, composición farmacéutica | |
UY31454A1 (es) | Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepcion oral sin lactosa | |
DOP2019000108A (es) | Procedimiento de tratamiento de dismenorrea y dolor menstrual | |
PL426908A1 (pl) | Kompozycja składników aktywnych wspomagająca leczenie niedrożności jajowodów |